CMCaroline McHutchison

Caroline McHutchison

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caroline McHutchison has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mild cognitive impairment in presymptomatic amyotrophic lateral sclerosis

    by Caroline McHutchison, Joanne Wuu, Stephanie Cosentino, Regla Saldana, Enjolie Vadella, Ana Benacerraf, Katja McBane, Alexa S. Gonzalez, Jessica H. Stark, Yindi Li, et al.

    Background: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are clinically and biologically related, and each may be preceded by a prodromal stage of disease. Mild cognitive and behavioural impairment (MCI/MBI) have also been observed in those with clinically manifest ALS. The primary aim of this study was to characterise MCI in presymptomatic ALS. Methods: Criteria for frontotemporal-related MCI (MCI-ft), which require evidence of subthreshold cognitive performance or decline, were adapted from existing frameworks for MCI in prodromal FTD, presymptomatic ALS and clinically manifest ALS. MCI-ft was characterised in 216 Pre-fALS participants (74 C9ORF72 , 94 SOD1 , 20 other pathogenic variant carriers and 28 non-carriers) with neuropsychological data at 807 study visits. All designations were reviewed by a research neuropsychologist, with consensus discussions as needed. Results: MCI-ft was observed in 15 (20%) C9ORF72 , 12 (13%) SOD1 and 3 (%) of other carriers at one or more study visits, compared to 1 (4%) non-carrier. Most visits with MCI-ft showed impairment affecting both language and executive functioning. Fluctuations in MCI-ft status between assessments were common. Conclusion: The observed frequency and temporal course of MCI-ft in presymptomatic ALS, using criteria based on subthreshold cognitive performance and decline, expands understanding of this phase of disease. These findings help to inform future research examining the risk of phenoconversion to clinically manifest disease and aid the design of disease prevention trials.


  • Open Access

    Conceptualizing cognition and behaviour across amyotrophic lateral sclerosis and frontotemporal dementia

    by Michael Benatar, Edward D Huey, Chiadi U Onyike, Caroline McHutchison, Maria Carmela Tartaglia, Megan S Barker, Sharon Abrahams, Joke De Vocht, Emma Rhodes, Yolande A Pijnenburg, et al.

    Cognitive and behavioural dysfunction in frontotemporal dementia (FTD) evolves along a clinical continuum from a clinically silent stage of disease, through a prodromal period, often referred to as mild cognitive impairment (MCI) and/or mild behavioural impairment (MBI), and into a clinically manifest stage recognized by the syndromes of behavioural variant FTD and primary progressive aphasia (PPA). Similar cognitive and behavioural manifestations of varying severity are also encountered in individuals with amyotrophic lateral sclerosis (ALS). Notwithstanding this phenotypic overlap as well as a degree of shared genetic risk and underlying pathology, the approach to phenotypic characterization and description meaningfully differs between the ALS and FTD communities. The problem is particularly evident within the ALS community when describing impairment in the prodromal versus clinically manifest disease stages. Pertinent considerations include the nature of cognitive and behavioural assessments, the nosology used to describe symptoms identified, including those encompassed by the terms ‘behavioural’ and ‘neuropsychiatric’, the operationalized criteria that define prodromal syndromes and clinically manifest disease, and the extent to which these criteria rely on longitudinal (versus cross-sectional) data. A multi-stakeholder workshop, held in London, Ontario (12–14 May 2025), brought together neurologists, psychiatrists, neuropsychologists, neuropathologists, neuroscientists and neurogeneticists studying ALS and FTD, to promote interdisciplinary dialogue and to define a research agenda that might be jointly tackled to address these critical issues. A new nosology for classifying frontotemporal-related behavioural and neuropsychiatric dysfunction, which could be used to support empirical evidence collection, is proposed alongside a list of cognitive, language, behavioural and neuropsychiatric symptoms to be considered in the evaluation of individuals with ALS. Research priorities for each of the ALS and FTD communities, as well as initiatives that should be undertaken jointly, are highlighted. The long-term goal is to harmonize approaches to phenotypic characterization, the nosology used to describe symptoms and the criteria used to define landmark stages along the clinical continua of the motor neuron and frontotemporal axes, irrespective of clinical stage.


  • Open Access

    Progress towards a biotypic biomarker profile for amyotrophic lateral sclerosis–frontotemporal spectrum disorders

    by Michael J Strong, Neil Donison, Ammar Al-Chalabi, Bradley Boeve, Elizabeth C Finger, Henne Holstege, Edward D Huey, Edward B Lee, Sarah J Marzi, Caroline McHutchison, et al.

    Determining the optimal timing of disease-modifying therapies for neurodegenerative disorders will necessitate identification of when the underlying pathobiological process becomes active, well in advance of the point at which clinical manifestations appear. Phenoconversion, the emergence of clinically manifest syndromes, may be preceded by years to decades of silent pathobiological activity that can only be mapped by an array of biomarkers. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementias (FTD), traditionally identified as distinct clinical syndromes, are increasingly recognized to exist along a spectrum of clinical syndromes with shared genetic risk and underlying pathology. This clinicopathological spectrum is underpinned by cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP-43) as the common neuropathological hallmark. In contrast, the majority of neuropathologically-defined frontotemporal lobar degeneration (FTLD) is associated with alterations in either TDP-43 metabolism (FTLD-TDP) or of the microtubule associated protein tau (FTLD-tau), with a smaller percentage associated with either autosomal dominant genetic mutations or impairments in the ubiquitin proteasome system. As the field of neurodegenerative disorders increasingly shifts towards the frameworks of a pathobiological definition of disease, there is a growing imperative to develop biomarkers that reflect the varied pathobiologies that underly these disorders, and to determine the sensitivity of such biomarkers to detect the presence of these pathobiologies before phenoconversion. To that end, an international workshop was convened in London, Canada in 2025 to review the evidence for existing or evolving biomarkers suitable for (i) the detection of either ALS or FTD pathobiology prior to phenoconversion and/or (ii) predict phenoconversion in at-risk individuals. Such biomarkers might be conceptualized as ‘biotypic biomarkers’, capturing their ability to describe an underlying pathophysiology whilst being agnostic to the emergent clinical manifestations. While currently no single biotypic marker can predict the emergence of ALS, FTD or their intersection, a multimodal approach to developing a biotypic biomarker profile holds promise for the detection of relevant pathobiological processes. The strength of such an approach would be augmented by also addressing issues of resiliency/susceptibility both in terms of genetic risk susceptibility profiles and developing sensitive biomarkers of genomic and cellular ageing. By including such non-traditional markers of disease, a more robust picture of not only the degenerative process but also of those factors that might potentially mitigate or drive a heightened probability of disease can be derived.

  • Open Access

    Stroke, Small‐Vessel Disease, and Occupation: Systematic Review and Data Analysis

    by Thomas Zhang, Una Clancy, Ayush Singh, Stephen Makin, Caroline McHutchison, Vera Cvoro, Carmen Arteaga‐Reyes, Daniela Jaime Garcia, Will Hewins, Michael Stringer, et al.

    Background: Novel risk factors for stroke, such as occupation, are increasingly under exploration. We investigate if specific occupational exposures and settings increase the risk of developing small‐vessel disease (SVD), including SVD‐related strokes. Methods: We performed a systematic review on stroke–occupation associations and then analyzed data from patients presenting to Lothian stroke services with mild ischemic stroke (modified Rankin Scale score ≤2). We performed magnetic resonance imaging and inquired about occupational status. We assessed relationships between high‐risk occupations (per Control to Substances Hazardous to Health guidelines) and standard occupational classifications (per Standard Occupational Classifications criteria) against white matter hyperintensity volumes, SVD score, and stroke subtype. Results: Our systematic review identified 37 papers assessing occupations/broad occupational classifications (n=13), psychosocial work‐related factors (n=11), and occupational exposure to hazardous substances (n=13). We then analyzed data from 414 participants and found, after adjustment for age, hypercholesterolemia, socioeconomic status, years of education, hypertension, diabetes, and smoking history, that high‐risk occupations were associated with higher SVD scores (odds ratio, 1.64 [95% CI, 1.07–2.54]; n=357; P =0.02) but not for lacunar stroke subtype (odds ratio, 1.03 [95% CI, 0.64–1.67]; n=358; P =0.90) or white matter hyperintensity volume (% intracranial volume) (β=−0.003 [95% CI, −0.015 to 0.008]; n=357; P =0.60). Examples of high‐risk occupations include drivers, engineers, and skilled trade workers. No associations were found for standard occupational classifications. Conclusions: This systematic review shows limited data on stroke–occupation associations. Our analysis showed that high‐risk occupations are associated with higher SVD scores but not stroke subtype. Registration: URL: www.crd.york.ac.uk/PROSPERO ; Unique Identifier: 42024466671.


  • Open Access

    Prioritizing neuropsychological research and care in Amyotrophic Lateral Sclerosis (ALS): building an international neuropsychological framework for ALS

    by Joke De Vocht, Emmet Costello, Caroline McHutchison, Ratko Radakovic, Juliette Foucher, Roisin McMackin, Colm Peelo, Leonard van Den Berg, Orla Hardiman, Philip Van Damme, et al.


  • Open Access

    Functional, Cognitive, Physical, and Vascular Outcomes 9 Years After Lacunar and Mild Cortical Ischemic Stroke

    by Daniela Jaime Garcia, Stephen D.J. Makin, Caroline A. McHutchison, Vera Cvoro, Maria Del C. Valdés Hernández, Eleni Sakka, Francesca M. Chappell, Fergus Doubal, Joanna M. Wardlaw

    Data on outcomes after minor stroke, especially lacunar stroke, are lacking or based on short follow-up. Outcome differences between lacunar and cortical stroke remain unclear but may provide insights into small vessel disease (SVD) etiology and prognosis. We report on dementia, death, recurrent stroke, and function up to 9 years after lacunar or minor cortical ischemic stroke. In this 9-year longitudinal observational cohort study, we prospectively recruited participants presenting with mild, nondisabling lacunar or cortical ischemic stroke to Lothian Stroke Services in Edinburgh, United Kingdom. At baseline, we collected data on sociodemographics, vascular risk factors, dependence, cognition, and brain MRI. At 9 years, we used questionnaires (including items from the Stroke Impact Scale) and hospital/general practitioner records to assess dementia, recurrent stroke, death, cardiac diseases, vascular risk factors, dependence, recovery, and functionality. We recruited 264 participants; clinical data were available for 243 participants (92%) (baseline mean age 67 years (SD 12), 42% female, 44% with lacunar stroke) and self-reported functional data for 96 (36%) at a mean follow-up of 8.5 years (SD 0.57). Dementia was diagnosed in 9.4% of participants with lacunar stroke and 12.4% of those with cortical stroke, with risk increasing with age (odds ratio [OR] 1.08; CI 1.030-1.130). Recurrent stroke occurred in one-third of all participants; risk increased with the presence of vascular risk factors (OR 2.27; CI 1.287-4.032). Participants with cortical stroke were more likely to die compared with those with lacunar stroke (χ2 = 8.2; p = 0.004). Age (OR 1.09; CI 1.051-1.133), male sex (female OR 0.40, CI 0.196-0.818), and white matter hyperintensities (OR 1.36; CI 1.112-1.664) increased risk of death. Moderate/severe disability was reported by 12% of participants and cognitive concerns by 49%-55%. Affected limb recovery and balance were worse after lacunar stroke (W = 705.5, p = 0.00). Long-term outcomes after minor stroke were frequently suboptimal and varied by stroke subtype, highlighting the lasting impact of both lacunar and mild cortical ischemic strokes on quality of life. Improving long-term outcomes after mild stroke remains an important target for refining clinical care and shaping future research directions.


  • Open Access

    Temporal course of cognitive and behavioural changes in motor neuron diseases

    by Caroline A McHutchison, Joanne Wuu, Corey T McMillan, Rosa Rademakers, Jeffrey Statland, Gang Wu, Evadnie Rampersaud, Jason Myers, Jessica P Hernandez, Sharon Abrahams, et al.

    Background: Cognitive and behavioural dysfunction may occur in people with motor neuron disease (MND), with some studies suggesting an association with theC9ORF72repeat expansion. Their onset and progression, however, is poorly understood. We explored how cognition and behaviour change over time, and whether demographic, clinical and genetic factors impact these changes.Methods: Participants with MND were recruited through the Phenotype-Genotype-Biomarker study. Every 3–6 months, the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was used to assess amyotrophic lateral sclerosis (ALS) specific (executive functioning, verbal fluency, language) and ALS non-specific (memory, visuospatial) functions. Informants reported on behaviour symptoms via semi-structured interview.Results: Participants with neuropsychological data at ≥3 visits were included (n=237, mean age=59, 60% male), of which 18 (8%) wereC9ORF72positive. Baseline cognitive impairment was apparent in 18 (8%), typically in ALS specific domains, and associated with lower education, but notC9ORF72status. Cognition, on average, remained stable over time, with two exceptions: (1)C9ORF72carriers declined in all ECAS domains, (2) 8%–9% of participants with baseline cognitive impairment further declined, primarily in the ALS non-specific domain, which was associated with less education. Behavioural symptoms were uncommon.Conclusions: In this study, cognitive dysfunction was less common than previously reported and remained stable over time for most. However, cognition declines longitudinally in a small subset, which is not entirely related toC9ORF72status. Our findings raise questions about the timing of cognitive impairment in MND, and whether it arises during early clinically manifest disease or even prior to motor manifestations.


  • Open Access

    Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity

    by Michael Benatar, Volkan Granit, Peter M Andersen, Anne-Laure Grignon, Caroline McHutchison, Stephanie Cosentino, Andrea Malaspina, Joanne Wuu

    Amyotrophic lateral sclerosis, when viewed as a biological entity rather than a clinical syndrome, probably evolves along a continuum, with the initial clinically silent phase eventually evolving into clinically manifest amyotrophic lateral sclerosis. Since motor neuron degeneration is incremental and cumulative over time, it stands to reason that the clinical syndrome of amyotrophic lateral sclerosis is probably preceded by a prodromal state characterized by minor motor abnormalities that are initially insufficient to permit a diagnosis of amyotrophic lateral sclerosis. This prodromal period, however, is usually missed, given the invariably long delays between symptom onset and diagnostic evaluation. The Pre-Symptomatic Familial ALS Study, a cohort study of pre-symptomatic gene mutation carriers, offers a unique opportunity to observe what is typically unseen. Here we describe the clinical characterization of 20 pre-symptomatic mutation carriers (in SOD1, FUS and C9orf72) whose phenoconversion to clinically manifest disease has been prospectively studied. In so doing, we observed a prodromal phase of mild motor impairment in 11 of 20 phenoconverters. Among the n = 12 SOD1 A4V mutation carriers, phenoconversion was characterized by abrupt onset of weakness, with a short (1–3.5 months) prodromal period observable in a small minority (n = 3); the observable prodrome invariably involved the lower motor neuron axis. By contrast, in all n = 3 SOD1 I113T mutation carriers, diffuse lower motor neuron and upper motor neuron signs evolved insidiously during a prodromal period that extended over a period of many years; prodromal manifestations eventually coalesced into a clinical syndrome that is recognizable as amyotrophic lateral sclerosis. Similarly, in all n = 3 C9orf72 hexanucleotide repeat expansion mutation carriers, focal or multifocal manifestations of disease evolved gradually over a prodromal period of 1–2 years. Clinically manifest ALS also emerged following a prodromal period of mild motor impairment, lasting >4 years and ∼9 months, respectively, in n = 2 with other gene mutations (SOD1 L106V and FUS c.521del6). On the basis of this empirical evidence, we conclude that mild motor impairment is an observable state that precedes clinically manifest disease in three of the most common genetic forms of amyotrophic lateral sclerosis (SOD1, FUS, C9orf72), and perhaps in all genetic amyotrophic lateral sclerosis; we also propose that this might be true of non-genetic amyotrophic lateral sclerosis. As a diagnostic label, mild motor impairment provides the language to describe the indeterminate (and sometimes intermediate) transition between the unaffected state and clinically manifest amyotrophic lateral sclerosis. Recognizing mild motor impairment as a distinct clinical entity should generate fresh urgency for developing biomarkers reflecting the earliest events in the degenerative cascade, with potential to reduce the diagnostic delay and to permit earlier therapeutic intervention.


  • Open Access

    Impact of Small Vessel Disease Progression on Long-term Cognitive and Functional Changes After Stroke

    by Una Clancy, Stephen D.J. Makin, Caroline A. McHutchison, Vera Cvoro, Francesca M. Chappell, Maria del C. Valdés Hernández, Eleni Sakka, Fergus Doubal, Joanna M. Wardlaw

    Background and Objectives The severity of white matter hyperintensities (WMH) at presentation with stroke is associated with poststroke dementia and dependency. However, WMH can decrease or increase after stroke; prediction of cognitive decline is imprecise; and there are few data assessing longitudinal interrelationships among changing WMH, cognition, and function after stroke, despite the clinical importance. Methods We recruited patients within 3 months of a minor ischemic stroke, defined as NIH Stroke Scale (NIHSS) score 2. Participants repeated MRI at 1 year and cognitive and mRS assessments at 1 and 3 years. We ran longitudinal mixed-effects models assessing change in Addenbrooke’s Cognitive Examination–Revised (ACE-R) and mRS scores. For mRS score, we assessed longitudinal WMH volumes (cube root; percentage intracranial volume [ICV]), adjusting for age, NIHSS score, ACE-R, stroke subtype, and time to assessment. For ACE-R score, we additionally adjusted for ICV, mRS, premorbid IQ, and vascular risk factors. We then used a multivariate model to jointly assess changing cognition/mRS score, adjusted for prognostic variables, using all available data. Results We recruited 264 patients; mean age was 66.9 (SD 11.8) years; 41.7% were female; and median mRS score was 1 (interquartile range 1–2). One year after stroke, normalized WMH volumes were associated more strongly with 1-year ACE-R score (β = −0.259, 95% CI −0.407 to −0.111 more WMH per 1-point ACE-R decrease, p = 0.001) compared to subacute WMH volumes and ACE-R score (β = 0.105, 95% CI −0.265 to 0.054, p = 0.195). Three-year mRS score was associated with 3-year ACE-R score (β = −0.272, 95% CI −0.429 to −0.115, p = 0.001). Combined change in baseline-1-year jointly assessed ACE-R/mRS scores was associated with fluctuating WMH volumes (F = 9.3, p = 0.03). Discussion After stroke, fluctuating WMH mean that 1-year, but not baseline, WMH volumes are associated strongly with contemporaneous cognitive scores. Covarying longitudinal decline in cognition and independence after stroke, central to dementia diagnosis, is associated with increasing WMH volumes.


  • Open Access

    Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases

    by Michael Benatar, Joanne Wuu, Caroline McHutchison, Ronald B Postuma, Bradley F Boeve, Ronald Petersen, Christopher A Ross, Howard Rosen, Jalayne J Arias, Stephanie Fradette, et al.

    Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis. While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinal muscular atrophy and frontotemporal dementia are also each preceded by a pre-symptomatic or prodromal period of varying duration, during which the underlying disease process unfolds, with associated compensatory changes and loss of inherent system redundancy. Key insights from these diseases highlight opportunities for discovery in amyotrophic lateral sclerosis. The development of biomarkers reflecting amyloid and tau has led to a shift in defining Alzheimer’s disease based on inferred underlying histopathology. Parkinson’s disease is unique among neurodegenerative diseases in the number and diversity of non-genetic biomarkers of pre-symptomatic disease, most notably REM sleep behaviour disorder. Huntington’s disease benefits from an ability to predict the likely timing of clinically manifest disease based on age and CAG-repeat length alongside reliable neuroimaging markers of atrophy. Spinal muscular atrophy clinical trials have highlighted the transformational value of early therapeutic intervention, and studies in frontotemporal dementia illustrate the differential role of biomarkers based on genotype. Similar advances in amyotrophic lateral sclerosis would transform our understanding of key events in pathogenesis, thereby dramatically accelerating progress towards disease prevention. Deciphering the biology of pre-symptomatic amyotrophic lateral sclerosis relies on a clear conceptual framework for defining the earliest stages of disease. Clinically manifest amyotrophic lateral sclerosis may emerge abruptly, especially among those who harbour genetic mutations associated with rapidly progressive amyotrophic lateral sclerosis. However, the disease may also evolve more gradually, revealing a prodromal period of mild motor impairment preceding phenoconversion to clinically manifest disease. Similarly, cognitive and behavioural impairment, when present, may emerge gradually, evolving through a prodromal period of mild cognitive impairment or mild behavioural impairment before progression to amyotrophic lateral sclerosis. Biomarkers are critically important to studying pre-symptomatic amyotrophic lateral sclerosis and essential to efforts to intervene therapeutically before clinically manifest disease emerges. The use of non-genetic biomarkers, however, presents challenges related to counselling, informed consent, communication of results and limited protections afforded by existing legislation. Experiences from pre-symptomatic genetic testing and counselling, and the legal protections against discrimination based on genetic data, may serve as a guide. Building on what we have learned—more broadly from other pre-symptomatic neurodegenerative diseases and specifically from amyotrophic lateral sclerosis gene mutation carriers—we present a road map to early intervention, and perhaps even disease prevention, for all forms of amyotrophic lateral sclerosis.